SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

2/13/23 3:35:59 PM ET

Industrial Specialties

Health Care

Get the next $AVNS alert in real time by email

SC 13G/A 1 AVNS-13G-2022.txt RGM AVNS 13G1 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Avanos Medical, Inc. ----------------------------------------------------------------------------- (Name of Issuer) Common Stock, $0.01 Par Value ----------------------------------------------------------------------------- (Title of Class of Securities) 05350V106 ----------------------------------------------------------------------------- (CUSIP Number) December 31, 2022 ----------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [_] Rule 13d-1(c) [_] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 05350V106 13G ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only). RGM Capital, LLC 06-16885711 ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS): (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION Delaware ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 0 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 2,653,104 _____________________________ (7) SOLE DISPOSITIVE POWER 0 _____________________________ (8) SHARED DISPOSITIVE POWER 2,653,104 ______________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,653,104 ------------------------------------------------------------------------------ (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ------------------------------------------------------------------------------ (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.71 % ------------------------------------------------------------------------------ (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IA ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 05350V106 13G ----------------------------------------------------------------------------- (1) NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). Robert G. Moses ----------------------------------------------------------------------------- (2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [_] (b) [_] ----------------------------------------------------------------------------- (3) SEC USE ONLY ----------------------------------------------------------------------------- (4) CITIZENSHIP OR PLACE OF ORGANIZATION United States ----------------------------------------------------------------------------- (5) SOLE VOTING POWER NUMBER OF SHARES 0 BENEFICIALLY OWNED _____________________________ BY EACH REPORTING PERSON WITH: (6) SHARED VOTING POWER 2,653,104 _____________________________ (7) SOLE DISPOSITIVE POWER 0 _____________________________ (8) SHARED DISPOSITIVE POWER 2,653,104 ______________________________ (9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,653,104 ------------------------------------------------------------------------------ (10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [_] ------------------------------------------------------------------------------ (11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 5.71 % ------------------------------------------------------------------------------ (12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) HC ============================================================================= ----------------------------------------------------------------------------- CUSIP NO. 05350V106 13G ----------------------------------------------------------------------------- Item 1. (a) Name of Issuer Avanos Medical, Inc. (b) Address of Issuer's Principal Executive Offices. 5405 Windward Parkway, Suite 100 South, Alpharetta, GA 30004 Item 2. (a) Name of Person Filing. Robert G. Moses RGM Capital, LLC (b) Address of Principal Business Office, or if None, Residence. 9010 Strada Stell Court, Suite 105, Naples, FL 34109 (c) Citizenship. United States (d) Title of Class of Securities. Common Stock, $0.01 Par Value (e) CUSIP Number. 05350V106 Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b) or (c),check whether the person filing is a: (a) [_] Broker or dealer registered under section 15 of the Act. (b) [_] Bank as defined in section 3(a)(6) of the Act. (c) [_] Insurance Company as defined in section 3(a)(19) of the Act. (d) [_] Investment Company registered under section 8 of the Investment Company Act. (e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E). (f) [_] Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F). (g) [x] Parent holding company or control person, in accordance with Sec.240.13d-1(b)(1)(ii)(G). (h) [_] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act. (i) [_] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940. (j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J). Item 4. Ownership. (a) Amount beneficially owned. 2,653,104 (b) Percent of class. 5.71 % (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 0 -------------------- (ii) Shared power to vote or to direct the vote 2,653,104 -------------------- (iii) Sole power to dispose or to direct the disposition of 0 -------------------- (iv) Shared power to dispose or to direct the disposition of 2,653,104 -------------------- Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ] Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Robert G. Moses is the managing member of RGM Capital, LLC, a Delaware limited liability company that serves as investment adviser to, and exercises investment discretion over, a number of investment accounts and investment vehicles. None of those investment accounts or investment vehicles has beneficial ownership of 5% or more of any class of the Common Stock. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company. Not applicable Item 8. Identification and Classification of Members of the Group. Not applicable Item 9. Notice of Dissolution of a Group. Not applicable Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: February 10, 2023 RGM CAPITAL, LLC* By: /s/ Robert G. Moses --------------------------- Name: Robert G. Moses Title: Managing Member Robert G. Moses* By: /s/ Robert G. Moses --------------------------- * The Reporting Persons disclaim beneficial ownership of the shares reported herein except to the extent of their pecuniary interest. EXHIBIT INDEX EXHIBIT B: Joint Acquisition Statement Pursuant to Section 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate. Date: February 10, 2023 RGM CAPITAL, LLC By: /s/ Robert G. Moses --------------------------- Name: Robert G. Moses Title: Managing Member Robert G. Moses By: /s/ Robert G. Moses ---------------------------

Get the next $AVNS alert in real time by email

Recent Analyst Ratings for

$AVNS

Date	Price Target	Rating	Analyst
7/25/2023		Overweight → Sector Weight	KeyBanc Capital Markets
5/22/2023	$31.00	Buy	CL King
2/24/2022	$47.00 → $41.00	Overweight	Keybanc
1/7/2022	$37.00 → $36.00	Underweight	Morgan Stanley
8/4/2021	$45.00 → $41.00	Underweight	Morgan Stanley
8/4/2021	$60.00 → $45.00	Overweight → Equal-Weight	Stephens
8/4/2021	$55.00 → $47.00	Overweight	Keybanc

More analyst ratings

SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

2/13/23 3:35:59 PM ET

$AVNS

Industrial Specialties

Health Care

Get the next $AVNS alert in real time by email

Recent Analyst Ratings for

$AVNS

Date	Price Target	Rating	Analyst
7/25/2023		Overweight → Sector Weight	KeyBanc Capital Markets
5/22/2023	$31.00	Buy	CL King
2/24/2022	$47.00 → $41.00	Overweight	Keybanc
1/7/2022	$37.00 → $36.00	Underweight	Morgan Stanley
8/4/2021	$45.00 → $41.00	Underweight	Morgan Stanley
8/4/2021	$60.00 → $45.00	Overweight → Equal-Weight	Stephens
8/4/2021	$55.00 → $47.00	Overweight	Keybanc

More analyst ratings

SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$AVNS

SEC Form SC 13G/A filed by Avanos Medical Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$AVNS

$AVNS
Analyst Ratings

Avanos Medical downgraded by KeyBanc Capital Markets

CL King initiated coverage on Avanos Medical with a new price target

Keybanc reiterated coverage on Avanos Medical with a new price target

$AVNS
Insider Purchases

Director Blackford Gary bought $659,300 worth of shares (60,000 units at $10.99), increasing direct ownership by 28% to 91,593 units (SEC Form 4)

Shimer Julie Ann bought $9,925 worth of shares (500 units at $19.85), increasing direct ownership by 1% to 50,090 units (SEC Form 4)

$AVNS
SEC Filings

SEC Form DEFA14A filed by Avanos Medical Inc.

Avanos Medical Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

SEC Form DEFA14A filed by Avanos Medical Inc.

$AVNS
Press Releases

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

Avanos Medical, Inc. and American Industrial Partners Receive Required Regulatory Approvals for Pending Merger

Avanos Medical, Inc. Announces First Quarter 2026 Results

$AVNS
Insider Trading

SEC Form 4 filed by Director Blackford Gary

SEC Form 4 filed by Director Egbuonu-Davis Lisa

SEC Form 4 filed by Director Franchini Indrani Lall

$AVNS
Leadership Updates

Krystal Biotech Set to Join S&P MidCap 400; Tutor Perini and V2X to Join S&P SmallCap 600

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

Avanos Medical Announces Appointment of Scott Galovan as Senior Vice President, Chief Financial Officer; David Pacitti Appointed to Board of Directors

$AVNS
Financials

Avanos Medical, Inc. Announces Fourth Quarter and Full-Year 2025 Results

Avanos Medical, Inc. to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results

Avanos Medical, Inc. Announces Third Quarter 2025 Results

$AVNS
Large Ownership Changes

SEC Form SC 13G filed by Avanos Medical Inc.